• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Inequity in adherence to empagliflozin and dulaglutide for type 2 diabetes in Aotearoa New Zealand.

作者信息

Mustafa Sara, Mayo Christopher, Paul Ryan, Rodrigues Mark, Murphy Rinki, Keenan Rawiri, Chepulis Lynne

机构信息

Division of Health, University of Waikato, Hamilton, Waikato, New Zealand.

Te Whatu Ora Health New Zealand, Hamilton, Waikato, New Zealand.

出版信息

Diabetes Obes Metab. 2025 Sep;27(9):5356-5361. doi: 10.1111/dom.16558. Epub 2025 Jun 24.

DOI:10.1111/dom.16558
PMID:40555685
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12326907/
Abstract
摘要

相似文献

1
Inequity in adherence to empagliflozin and dulaglutide for type 2 diabetes in Aotearoa New Zealand.新西兰奥特亚罗瓦地区在2型糖尿病患者使用恩格列净和度拉糖肽治疗方面的依从性差异。
Diabetes Obes Metab. 2025 Sep;27(9):5356-5361. doi: 10.1111/dom.16558. Epub 2025 Jun 24.
2
Comparison of Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes : Two Target Trial Emulation Studies.司美格鲁肽或度拉鲁肽与恩格列净治疗2型糖尿病患者死亡风险和心血管结局的比较：两项目标试验模拟研究
Ann Intern Med. 2025 Jul;178(7):930-939. doi: 10.7326/ANNALS-24-00775. Epub 2025 Jun 17.
3
Children and adolescents with type 1 diabetes in Aotearoa New Zealand: An online survey of workforce and outcomes 2021.新西兰奥塔哥地区 1 型糖尿病儿童和青少年：2021 年劳动力和结果的在线调查。
J Paediatr Child Health. 2024 Jun;60(6):222-228. doi: 10.1111/jpc.16566. Epub 2024 May 15.
4
Pirfenidone alone or combined with either dulaglutide or empagliflozin protects against fructose-induced Parkinsonian features in rats.
Behav Pharmacol. 2025 Aug 1;36(5):322-336. doi: 10.1097/FBP.0000000000000835. Epub 2025 Jun 19.
5
Refractive errors, amblyopia risk factors and vision screening in children aged 7-10 years in Aotearoa New Zealand.新西兰奥特亚罗瓦7至10岁儿童的屈光不正、弱视危险因素及视力筛查
Clin Exp Optom. 2024 Oct 7:1-6. doi: 10.1080/08164622.2024.2410036.
6
Kidney and Cardiovascular Effectiveness of Empagliflozin Compared With Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes.恩格列净与二肽基肽酶-4 抑制剂比较在 2 型糖尿病患者中的肾脏和心血管有效性。
Am J Cardiol. 2024 Jun 15;221:52-63. doi: 10.1016/j.amjcard.2024.04.011. Epub 2024 Apr 17.
7
The need for palliative care in Aotearoa New Zealand.
N Z Med J. 2025 Jul 25;138(1619):14-21. doi: 10.26635/6965.6933.
8
"I don't think service changed, I think people changed": Palliative care delivery in Aotearoa/New Zealand after COVID-19.“我认为服务没有改变，而是人变了”：新冠疫情后新西兰的姑息治疗服务
Palliat Care Soc Pract. 2025 Jun 24;19:26323524251343095. doi: 10.1177/26323524251343095. eCollection 2025.
9
Health service utilization among autistic youth in Aotearoa New Zealand: A nationwide cross-sectional study.新西兰奥特亚罗瓦自闭症青少年的医疗服务利用情况：一项全国性横断面研究。
Autism. 2025 May;29(5):1143-1156. doi: 10.1177/13623613241298352. Epub 2024 Dec 3.
10
Health Care Utilization and Costs Associated With Empagliflozin in Older Adults With Type 2 Diabetes.恩格列净治疗老年 2 型糖尿病患者的医疗利用度和费用。
Diabetes Care. 2024 Nov 1;47(11):1900-1907. doi: 10.2337/dc24-0270.

本文引用的文献

1
Real world initiation of newly funded empagliflozin and dulaglutide under special authority for patients with type 2 diabetes in New Zealand.在新西兰，针对2型糖尿病患者，在特殊授权下新获批的恩格列净和度拉鲁肽的真实世界起始治疗情况。
BMC Health Serv Res. 2025 Mar 26;25(1):433. doi: 10.1186/s12913-025-12601-3.
2
Ethnic differences in metabolic achievement between Māori, Pacific, and European New Zealanders with type 2 diabetes.新西兰 2 型糖尿病患者中毛利人、太平洋岛民和欧洲裔在代谢达标方面的种族差异。
Diabetes Res Clin Pract. 2022 Jul;189:109910. doi: 10.1016/j.diabres.2022.109910. Epub 2022 May 10.
3
Metformin adherence in patients with type 2 diabetes and its association with glycated haemoglobin levels.二甲双胍在 2 型糖尿病患者中的依从性及其与糖化血红蛋白水平的关系。
J Prim Health Care. 2020 Dec;12(4):318-326. doi: 10.1071/HC20043.
4
Experiences of Māori of Aotearoa New Zealand's public health system: a systematic review of two decades of published qualitative research.新西兰毛利人对公共卫生系统的体验：对二十年来发表的定性研究的系统评价。
Aust N Z J Public Health. 2020 Jun;44(3):193-200. doi: 10.1111/1753-6405.12971. Epub 2020 Apr 20.
5
Comparison of medication adherence and persistence in type 2 diabetes: A systematic review and meta-analysis.比较 2 型糖尿病患者的药物依从性和持久性：系统评价和荟萃分析。
Diabetes Obes Metab. 2018 Apr;20(4):1040-1043. doi: 10.1111/dom.13160. Epub 2017 Dec 12.
6
Good and poor adherence: optimal cut-point for adherence measures using administrative claims data.良好依从性与不良依从性：使用行政索赔数据进行依从性测量的最佳切点
Curr Med Res Opin. 2009 Sep;25(9):2303-10. doi: 10.1185/03007990903126833.